Clinical Trials Browser

Phase 1 × selinexor × Plasma cell × Clear all

NCT04640779 2026-01-06

Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma

Phase 1 Active not recruiting

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT02199665 2025-11-03

SINE

Phase 1 Completed

Multiple Myeloma

NCT06225310 2025-01-16

KPT-IST-391

Phase 1 Recruiting

Multiple Myeloma

NCT04519476 2023-10-31

Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.

Phase 1 Unknown

Multiple Myeloma

NCT01607892 2023-01-26

Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer

Phase 1 Completed

286 enrolled 26 charts

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02831686 2020-11-24

A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma

Phase 1 Completed

Multiple Myeloma